EMA Authorised: Xgeva (denosumab) — Amgen Europe B.V.

View source ↗

Summary

European Medicines Agency authorised Xgeva (denosumab) for giant cell tumor of bone, expanding its indications for this bone neoplasm. Decision date: 29 July 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Xgeva (denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Amgen Europe B.V.. Decision date: 29/07/2025